Cancer-related inflammation
Open accessThe DOI matches its Crossref record; 174 of the 175 references it cites were found in a registry or an index.
Abstract
The mediators and cellular effectors of inflammation are important constituents of the local environment of tumours. In some types of cancer, inflammatory conditions are present before a malignant change occurs. Conversely, in other types of cancer, an oncogenic change induces an inflammatory microenvironment that promotes the development of tumours. Regardless of its origin, 'smouldering' inflammation in the tumour microenvironment has many tumour-promoting effects. It aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and alters responses to hormones and chemotherapeutic agents. The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of these processes also occur in cancer as most of them are inflammation-related, including hypoxia-induced neovascularization, endothelial dysfunction, permeability of the microvasculature and the upregulation of adhesion molecules to facilitate the recruitment of cells30,31.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, cytokine production can be triggered by oncogenic transformation, metabolic alteration, cell death, hypoxia, and the use of anti-cancer drugs (10).”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing anti-tumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15)”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Excessive or dysregulated inflammation is a major driver of tissue damage and the pathogenesis of numerous diseases, including stroke, Parkinson’s disease, atherosclerosis, and cancer [9,30,31,32,33].”
From Picroside II as a Potential Anti-Inflammatory Agent (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, rather than the dogma that oncogenesis is intrinsically triggered in pre-neoplastic cells, environmental factors, such as infection, stress, obesity, aging and smoking, each of which can induce chronic inflammation, could be a major cause of oncogenesis (4, 6, 9, 233).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [6]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746 · cited 1×
“jpg" NDATA ITEM> ]> Links between cancer and inflammation were first made in the nineteenth century, on the basis of observations that tumours often arose at sites of chronic inflammation and that inflammatory cells were present in biopsied samples from tumour”
Self-citationMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“TAMs and related cell types in mouse and human tumours generally have an M2 phenotype, which is oriented towards promoting tumour growth, remodelling tissues, promoting angiogenesis and suppressing adaptive immunity&hairsp”
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“This type of response might also contribute to successful chemotherapy or radiotherapy, according to recent data obtained by Lionel Apetoh and colleague”
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032 · cited 1×
“Cancer-related inflammation and adaptive immunity There is strong evidence from genetic studies of mouse models that cells of the adaptive immune system carry out surveillance and can eliminate nascent tumours (a process called immuno-editing”
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790 · cited 1×
“This transcription factor is constitutively activated both in tumour cells and in immune cells, and is involved in oncogenesis and inhibition of apoptosi”
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695 · cited 1×
“TAMs have been described as “obligate partners for tumour-cell migration, invasion and metastasis&rdquo”
Cited by
Items 301–400 of 1,085
Tumor-induced perturbations of cytokines and immune cell networks
Burkholder, B., Huang, R.-Y., Burgess, R., Luo, S., Jones, V. S., Zhang, W., Lv, Z.-Q., Gao, C.-Y., Wang, B.-L., Zhang, Y.-M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.004 · Cited by 356
“The clinical significance of this was recently confirmed in a study that reported lower rates of both somatic genomic anomalies and progression to esophageal adenocarcinoma in patients with Barrett's esophagus who routinely took non-steroidal inflammatory drugs (NSAIDs) [23,36].”
BackgroundInfluentialFerroptosis in Cancer Cell Biology
Bebber, C. M., Müller, F., Prieto Clemente, L., Weber, J., & von Karstedt, S. (2020) · Cancers · doi:10.3390/cancers12010164 · Cited by 354
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., Yuan, Z.-R., Roberts, A. I., Zhang, L., Zheng, B., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.08.013 · Cited by 361
“…progression according to the observations that some cancers frequently occurred with infectious diseases and other chronic inflammations, as well as the reduced cancer incidence in individuals taking anti-inflammation medications (Coussens and Werb, 2002; Mantovani et al., 2008; Trinchieri, 2012).”
BackgroundMesenchymal stromal cell ‘licensing’: a multistep process
Krampera, M. (2011) · Leukemia · doi:10.1038/leu.2011.108 · Cited by 358
Mechanisms of Cancer Resistance to Immunotherapy
Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01290 · Cited by 353
The integration of inflammaging in age-related diseases
Fulop, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 348
Cavalli, G., Colafrancesco, S., Emmi, G., Imazio, M., Lopalco, G., Maggio, M. C., Sota, J., & Dinarello, C. A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102763 · Cited by 346
“Locally, a pro-inflammatory tumor microenvironment promotes inflammation-mediated immunosuppression, cancer cell survival, and tumor progression [24,248].”
BackgroundHow ageing processes influence cancer
de Magalhães, J. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3497 · Cited by 367
Chen, X.-L., Xue, L., Wang, W., Chen, H.-N., Zhang, W.-H., Liu, K., Chen, X.-Z., Yang, K., Zhang, B., Chen, Z.-X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5629 · Cited by 330
Hirsch, H. A., Iliopoulos, D., Joshi, A., Zhang, Y., Jaeger, S. A., Bulyk, M., Tsichlis, P. N., Shirley Liu, X., & Struhl, K. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.022 · Cited by 359
“For example, patients diagnosed with metabolic syndrome, inflammatory diseases, and autoimmune conditions show increased incidence and aggressiveness of tumor formation (Giovannucci, 2007; Mantovani et al., 2008; Pischon et al., 2008).”
Huh, S. J., Liang, S., Sharma, A., Dong, C., & Robertson, G. P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4442 · Cited by 352
“Tumor infiltration by immune cells occurs in most tumors (46).”
BackgroundHarnessing tumor‐associated macrophages as aids for cancer immunotherapy
Li, X., Liu, R., Su, X., Pan, Y., Han, X., Shao, C., & Shi, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1102-3 · Cited by 364
Liu, J., Li, S., Zhang, S., Liu, Y., Ma, L., Zhu, J., Xin, Y., Wang, Y., Yang, C., & Cheng, Y. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22964 · Cited by 364
Tissue homeostasis and inflammation
Meizlish, M. L., Franklin, R. A., Zhou, X., & Medzhitov, R. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-061020-053734 · Cited by 364
Wang, H., Tian, T., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168470 · Cited by 364
“Studies have shown that TAMs predominantly come from circulating inflammatory monocytes, which can be recruited by multiple chemokines including CC-chemokine ligands 2 and 5 (CCL2 and CCL5) and cytokines colony stimulating factor 1(CSF1) [28,29].”
BackgroundMantovani, A., Petracca, G., Beatrice, G., Csermely, A., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut · doi:10.1136/gutjnl-2021-324191 · Cited by 363
Self-citationWang, J., Li, D., Cang, H., & Guo, B. (2019) · Cancer Medicine · doi:10.1002/cam4.2327 · Cited by 349
RIP3: a molecular switch for necrosis and inflammation
Moriwaki, K., & Chan, F. K.-M. (2013) · Genes & Development · doi:10.1101/gad.223321.113 · Cited by 355
“Because necrosis also facilitates inflammation, its effect on inflammation in the tumor microenvironment has to be carefully considered (Mantovani et al. 2008).”
BackgroundTumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.
Quatromoni, J. G., & Eruslanov, E. B. (2012) · Europe PMC (PubMed Central) · Cited by 458
Targeting AMPK for cancer prevention and treatment
Li, W., Saud, S. M., Young, M. R., Chen, G., & Hua, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3629 · Cited by 355
Loh, C.-Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00048 · Cited by 348
Shen, M., Hu, P., Donskov, F., Wang, G., Liu, Q., & Du, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098259 · Cited by 347
“Stromal cells, blood vessels and infiltrating inflammatory cells are major components of the tumor microenvironment [2].”
Resolution of inflammation: An organizing principle in biology and medicine
Panigrahy, D., Gilligan, M. M., Serhan, C. N., & Kashfi, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107879 · Cited by 340
Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents
Tasneem, S., Liu, B., Li, B., Choudhary, M. I., & Wang, W. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.001 · Cited by 358
Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression
Park, J., Euhus, D. M., & Scherer, P. E. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0030 · Cited by 348
Zhou, S.-L., Dai, Z., Zhou, Z.-J., Wang, X.-Y., Yang, G.-H., Wang, Z., Huang, X.-W., Fan, J., & Zhou, J. (2012) · Hepatology · doi:10.1002/hep.25907 · Cited by 356
“The inflammatory environment includes inflammatory cells and inflammatory mediators (for example, chemokines, cytokines, and prostaglandins).(6) Chemokines are emerging as key mediators not only in the homing of cancer cells to metastatic sites but also in the recruitment of a number of different cell types to the tum…”
BackgroundWang, J., Fang, X., Ge, L., Cao, F., Zhao, L., Wang, Z., & Xiao, W. (2018) · PLOS ONE · doi:10.1371/journal.pone.0197563 · Cited by 349
Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
Song, L., Asgharzadeh, S., Salo, J., Engell, K., Wu, H.-W., Sposto, R., Ara, T., Silverman, A. M., DeClerck, Y. A., Seeger, R. C., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37869 · Cited by 342
“TAMs are often the most abundant inflammatory cells in the tumor microenvironment (24, 45).”
BackgroundMantovani, A., Sica, A., Allavena, P., Garlanda, C., & Locati, M. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.02.008 · Cited by 350
Self-citationThe neutrophil-to-lymphocyte ratio: a narrative review
Socorro Faria, S., Fernandes Jr, P. C., Barbosa Silva, M. J., Lima, V. C., Fontes, W., Freitas-Junior, R., Eterovic, A. K., & Forget, P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.702 · Cited by 332
“On the other side, immune response associated with BC concerns primarily lymphocytes, with a depressed cellular immunity, a decreased number of CD4 lymphocytes and an increased CD8 lymphocytes activation [26].”
BackgroundInfluentialClinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Meyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108121108 · Cited by 346
“These mediators were found to support tumor development by stimulating protumor mutations, resistance to apoptosis, and angiogenesis (7, 8).”
BackgroundKannaiyan, R., Shanmugam, M. K., & Sethi, G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.10.025 · Cited by 346
Tumour burden and efficacy of immune-checkpoint inhibitors
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00564-3 · Cited by 350
The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer
Liu, X., Wu, S., Yang, Y., Zhao, M., Zhu, G., & Hou, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.003 · Cited by 348
Drosophila melanogaster: A Model Organism to Study Cancer
Mirzoyan, Z., Sollazzo, M., Allocca, M., Valenza, A. M., Grifoni, D., & Bellosta, P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00051 · Cited by 317
“Inflammation in tumor development acts as “tug and war” since it may promote survival of tumor cells by favoring angiogenesis, by reducing the natural immune responses and by altering responses to chemotherapeutic agents (Mantovani et al., 2008; Wu and Zhou, 2009).”
BackgroundS100A8/A9 activate key genes and pathways in colon tumor progression
Ichikawa, M., Williams, R., Wang, L., Vogl, T., & Srikrishna, G. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0394 · Cited by 346
“Cells of the tumor microenvironment contribute to tumor growth and metastasis through complex interactions with tumor cells [58–60].”
BackgroundArtinyan, A., Orcutt, S. T., Anaya, D. A., Richardson, P., Chen, G. J., & Berger, D. H. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000854 · Cited by 345
Inflammation as “common soil” of the multifactorial diseases
Scrivo, R., Vasile, M., Bartosiewicz, I., & Valesini, G. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.12.006 · Cited by 336
“There are two different pathways linking the inflammation with tumorigenesis: an extrinsic pathway mediated by chronic inflammation (inflammation-induced cancer) and an intrinsic pathway in which genetic alterations, in the absence of an underlying inflammation, initiate a tumour-driven host immune response leading to…”
BackgroundTeramukai, S., Kitano, T., Kishida, Y., Kawahara, M., Kubota, K., Komuta, K., Minato, K., Mio, T., Fujita, Y., Yonei, T., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.01.023 · Cited by 344
Kartikasari, A. E. R., Huertas, C. S., Mitchell, A., & Plebanski, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692142 · Cited by 343
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing antitumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15) (Figure…”
BackgroundChronic Periodontitis and the Incidence of Head and Neck Squamous Cell Carcinoma
Tezal, M., Sullivan, M. A., Hyland, A., Marshall, J. R., Stoler, D., Reid, M. E., Loree, T. R., Rigual, N. R., Merzianu, M., Hauck, L., et al. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0334 · Cited by 331
“Continuous stimulation of cellular proliferation by chronic inflammation may be responsible for this histologic type (4, 5).”
BackgroundInfluentialCancer therapy in the necroptosis era
Su, Z., Yang, Z., Xie, L., DeWitt, J. P., & Chen, Y. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.8 · Cited by 333
“Numerous studies have suggested that inflammatory microenvironment may promote tumor development by stimulating angiogenesis and metastasis, attenuating adaptive immune responses, and increasing drug resistance.(50) Therefore, another concern is whether necroptosis-related inflammation has a deleterious role in tumor…”
BackgroundXu, F., Cui, W.-Q., Wei, Y., Cui, J., Qiu, J., Hu, L.-L., Gong, W.-Y., Dong, J.-C., & Liu, B.-J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0878-0 · Cited by 331
Li, T., Morgan, M. J., Choksi, S., Zhang, Y., Kim, Y.-S., & Liu, Z.-G. (2010) · Nature Immunology · doi:10.1038/ni.1918 · Cited by 339
“(d) Immunoblot analysis of lysates of monocytes 48 h after transfection of miRNA inhibitors containing control oligonucleotides (Ctrl) or combinations of pooled inhibitors for miR-15a (15a), miR-16 (16) and miR-223 (223), probed with antibody to IKKα (antiIKKα) and anti-IKKβ.”
Role of autophagy in suppression of inflammation and cancer
White, E., Karp, C., Strohecker, A. M., Guo, Y., & Mathew, R. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.12.008 · Cited by 328
“In turn, oncogenic events promote inflammation that can enable tumor progression by altering the tumor microenvironment [43].”
Oxidative stress promotes myofibroblast differentiation and tumour spreading
Toullec, A., Gerald, D., Despouy, G., Bourachot, B., Cardon, M., Lefort, S., Richardson, M., Rigaill, G., Parrini, M., Lucchesi, C., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000073 · Cited by 339
“…growth and metastases 2010 EMBO Molecular Medicine 223 224 (Condeelis & Pollard, 2006; Coussens & Werb, 2002; de Visser et al, 2006; Erez et al, 2010; Grivennikov & Karin, 2010; Joyce & Pollard, 2009; Karin & Greten, 2005; Mantovani et al, 2008; Radisky & Radisky, 2007; van Kempen et al, 2006).”
The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
Charles, K. A., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R. G., Kollias, G., Smyth, J. F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39065 · Cited by 338
Self-citationPucci, F., Venneri, M. A., Biziato, D., Nonis, A., Moi, D., Sica, A., Di Serio, C., Naldini, L., & De Palma, M. (2009) · Blood · doi:10.1182/blood-2009-01-200931 · Cited by 328
Self-citationBhatti, I., Peacock, O., Lloyd, G., Larvin, M., & Hall, R. I. (2010) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2009.08.041 · Cited by 333
Stimuli-sensitive nanopreparations for combination cancer therapy
Jhaveri, A., Deshpande, P., & Torchilin, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.002 · Cited by 334
“The internal cues or triggers which are commonly encountered in tumors include a lowered interstitial pH [8,9], high intracellular glutathione levels [10,11], various enzymes over-expressed or differentially expressed by tumors [12,13] and an increase in temperature (hyperthermia) that accompanies inflammation [14–16].”
BackgroundTeng, J.-F., Mei, Q.-B., Zhou, X.-G., Tang, Y., Xiong, R., Qiu, W.-Q., Pan, R., Law, B. Y.-K., Wong, V. K.-W., Yu, C.-L., et al. (2020) · Cancers · doi:10.3390/cancers12010193 · Cited by 332
“Emerging evidences indicate that inflammation plays an important role in the tumor development, including initiation, growth, invasion and metastasis [45].”
BackgroundMultifaceted link between cancer and inflammation
Sethi, G., Shanmugam, M. K., Ramachandran, L., Kumar, A. P., & Tergaonkar, V. (2012) · Bioscience Reports · doi:10.1042/bsr20100136 · Cited by 333
Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., Balsamo, M., Conte, R., Benelli, R., Minghelli, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2544 · Cited by 324
“Thus, although various potentially defensive effector cells are recruited at the tumor site, their antitumor activity may be downregulated mostly by factors produced by tumor cells or even by tumor-associated macrophages or stromal cells (21, 22, 30).”
BackgroundTumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer
Erreni, M., Mantovani, A., & Allavena, P. (2011) · Cancer Microenvironment · doi:10.1007/s12307-010-0052-5 · Cited by 325
“Indeed, most studies have shown that TAM exert several pro-tumor functions [ 19 , 100, 101].”
BackgroundSelf-citationCancer and Inflammation: Promise for Biologic Therapy
Demaria, S., Pikarsky, E., Karin, M., Coussens, L. M., Chen, Y.-C., El-Omar, E. M., Trinchieri, G., Dubinett, S. M., Mao, J. T., Szabo, E., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32e74 · Cited by 325
“However, the critical role of inflammatory cells in cancers that cannot be linked to a preexisting inflammatory condition has been recognized only recently.(3) Oncogenes target directly or indirectly proinflammatory pathways.”
BackgroundInfluentialForcing form and function: biomechanical regulation of tumor evolution
Yu, H., Mouw, J. K., & Weaver, V. M. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.08.015 · Cited by 321
Are Mast Cells MASTers in Cancer?
Varricchi, G., Galdiero, M. R., Loffredo, S., Marone, G., Iannone, R., Marone, G., & Granata, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00424 · Cited by 323
“Prolonged low-grade inflammation or smoldering inflammation is a hallmark of cancer (27, 28).”
BackgroundTumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Iismaa, S. E., Mearns, B. M., Lorand, L., & Graham, R. M. (2009) · Physiological Reviews · doi:10.1152/physrev.00044.2008 · Cited by 328
“flammatory responses (179) and tissue injury/remodeling”
Metabolic origins of spatial organization in the tumor microenvironment
Carmona-Fontaine, C., Deforet, M., Akkari, L., Thompson, C. B., Joyce, J. A., & Xavier, J. B. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700600114 · Cited by 323
Cytokines as a key component of cancer-related inflammation
Germano, G., Allavena, P., & Mantovani, A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.014 · Cited by 331
Self-citationPrognostic Value of PLR in Various Cancers: A Meta-Analysis
Zhou, X., Du, Y., Huang, Z., Xu, J., Qiu, T., Wang, J., Wang, T., Zhu, W., & Liu, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101119 · Cited by 330
Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans
Morris, T., Stables, M., Hobbs, A., de Souza, P., Colville-Nash, P., Warner, T., Newson, J., Bellingan, G., & Gilroy, D. W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900477 · Cited by 322
Elkabets, M., Ribeiro, V. S. G., Dinarello, C. A., Ostrand‐Rosenberg, S., Di Santo, J. P., Apte, R. N., & Vosshenrich, C. A. J. (2010) · European Journal of Immunology · doi:10.1002/eji.201041037 · Cited by 319
“The hallmarks of cancer-related inflammation include the presence at the tumor site of cytokines such as IL-1b, TNF-a, IL-6 and IL-23 [1–3].”
BackgroundInfluentialRadiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Haabeth, O. A. W., Lorvik, K. B., Hammarström, C., Donaldson, I. M., Haraldsen, G., Bogen, B., & Corthay, A. (2011) · Nature Communications · doi:10.1038/ncomms1239 · Cited by 318
Anti-Inflammatory Treatments for Chronic Diseases: A Review
Laveti, D., Kumar, M., Hemalatha, R., Sistla, R., Naidu, V., Talla, V., Verma, V., Kaur, N., & Nagpal, R. (2013) · Inflammation & Allergy-Drug Targets · doi:10.2174/18715281113129990053 · Cited by 325
“In certain tumor models, TNF- has been observed to stimulate fibroblasts or tumor cell growth [30], and most evidences have advocated its potential involvement in metastasis.”
BackgroundXu, X. R., Yousef, G. M., & Ni, H. (2018) · Blood · doi:10.1182/blood-2017-05-743187 · Cited by 325
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Basu, A., Ramamoorthi, G., Albert, G., Gallen, C., Beyer, A., Snyder, C., Koski, G., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 321
“Binding of IL-4 to IL-4 receptors on immune cells leads to STAT6 phosphorylation, nuclear translocation, and expression of GATA3 transcription factor, resulting in TH2 cytokine secretion and eventual tumor growth and metastasis (26, 27).”
BackgroundThe IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer
WANG, S.-W., & SUN, Y.-M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2259 · Cited by 320
Inflammation: A driving force speeds cancer metastasis
Wu, Y., & Zhou, B. P. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9699 · Cited by 327
Buckwheat as a Functional Food and Its Effects on Health
Giménez-Bastida, J. A., & Zieliński, H. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b02498 · Cited by 306
Hong, X., Cui, B., Wang, M., Yang, Z., Wang, L., & Xu, Q. (2015) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.236.297 · Cited by 326
Nistico, P., Bissell, M. J., & Radisky, D. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011908 · Cited by 313
“However, aberrant activation of the immune system can also promote tumor development, as chronic activation of inflammatory responses has been directly linked to development of cancer (Tan and Coussens 2007; Mantovani et al. 2008).”
BackgroundIL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation
Li, Y., Wang, L., Pappan, L., Galliher-Beckley, A., & Shi, J. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-87 · Cited by 319
“Interestingly, inflammatory cells and mediators are present in every tumor, including those that are not developed from chronic inflammation [1,2].”
BackgroundAn Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy
Tavaré, R., Escuin-Ordinas, H., Mok, S., McCracken, M. N., Zettlitz, K. A., Salazar, F. B., Witte, O. N., Ribas, A., & Wu, A. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1707 · Cited by 320
“The dynamic tumor microenvironment and tumor heterogeneity have become important topics in both preclinical and clinical studies (1-3) but the ability to monitor changes in the immune status of metastatic cancers is limited.”
BackgroundCCL2/CCR2 signaling in cancer pathogenesis
Hao, Q., Vadgama, J. V., & Wang, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00589-8 · Cited by 315
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 312
Inflammation and colorectal cancer
Kraus, S., & Arber, N. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.006 · Cited by 314
“This link was made on the basis of several observations (reviewed in [1 ]):”
Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols
Gupta, S. C., Tyagi, A. K., Deshmukh-Taskar, P., Hinojosa, M., Prasad, S., & Aggarwal, B. B. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.006 · Cited by 313
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment
Sato, Y., Goto, Y., Narita, N., & Hoon, D. S. B. (2009) · Cancer Microenvironment · doi:10.1007/s12307-009-0022-y · Cited by 319
“Recent studies have revealed that chronic inflammation increases the risk of cancer development and progression [1].”
BackgroundTertiary lymphoid structures in anticancer immunity
Teillaud, J.-L., Houel, A., Panouillot, M., Riffard, C., & Dieu-Nosjean, M.-C. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 293
“The requirement for a chronic inflammatory context for formation and maintenance of TLS is seemingly paradoxical considering the well-documented pro-tumoural effect of chronic inflammation on tumour development and the formation of metastases 33,34 .”
Zhong, J.-H., Huang, D.-H., & Chen, Z.-Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18856 · Cited by 307
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Cekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304
“CD45 þ cells were enriched from these suspensions at 4 C and defined by flow cytometry as macrophages (F4/80 þ ), myeloid DCs (F4/80 À /CD11c”
InfluentialYing, H.-Q., Deng, Q.-W., He, B.-S., Pan, Y.-Q., Wang, F., Sun, H.-L., Chen, J., Liu, X., & Wang, S.-K. (2014) · Medical Oncology · doi:10.1007/s12032-014-0305-0 · Cited by 317
“In addition to aids proliferation and survival of malignant cells, angiogenesis and metastasis of CRC, cancer-related inflammatory response subverts adaptive immune responses and alters responses to chemotherapeutic agents [5].”
BackgroundTargeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival
Cieslewicz, M., Tang, J., Yu, J. L., Cao, H., Zavaljevski, M., Motoyama, K., Lieber, A., Raines, E. W., & Pun, S. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312197110 · Cited by 314
“Associated with a shift to the M2 phenotype, TAMs have been shown to promote tumor cell growth, angiogenesis, metastasis, and immune evasion through the recruitment of regulatory T cells (29, 30).”
BackgroundWang, H., Feng, Z., Wang, Y., Zhou, R., Yang, Z., & Xu, B. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09783 · Cited by 315
Takahashi-Kanemitsu, A., Knight, C. T., & Hatakeyama, M. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0339-5 · Cited by 299
Chittezhath, M., Dhillon, M. K., Lim, J. Y., Laoui, D., Shalova, I. N., Teo, Y. L., Chen, J., Kamaraj, R., Raman, L., Lum, J., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.014 · Cited by 308
“Monocytes and macrophages represent the major inflammatory infiltrate associated within most solid tumors (Mantovani et al., 2008; Noy and Pollard, 2014), and their recruitment and activation at these sites is largely regulated by tumor-derived signals including chemokines, cytokines, and endogenous signals (Mantovani…”
BackgroundInfluentialDe Santo, C., Arscott, R., Booth, S., Karydis, I., Jones, M., Asher, R., Salio, M., Middleton, M., & Cerundolo, V. (2010) · Nature Immunology · doi:10.1038/ni.1942 · Cited by 304
“1942" language="eng" relation="no"> Several types of myeloid cells can promote tumor progression either directly, by inhibiting tumor-specific immune responses, or indirectly, by promoting angiogenesis, tumor growth and tissue remodelin”
BackgroundProgrammed assembly of 3-dimensional microtissues with defined cellular connectivity
Gartner, Z. J., & Bertozzi, C. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900717106 · Cited by 315
“This simple paracrine signaling network emulates cytokine-dependent immune cell expansion (25, 26) as well as tumor cell proliferation at sites of inflammation (27).”
BackgroundThe Role of Tumor-Associated Neutrophils in Colorectal Cancer
Mizuno, R., Kawada, K., Itatani, Y., Ogawa, R., Kiyasu, Y., & Sakai, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030529 · Cited by 316
“Tumor cells often produce several inflammatory chemokines, including neutrophil-attracting CXC-chemokines [22,23].”
BackgroundThe Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis
Nishida, A., & Andoh, A. (2025) · Cells · doi:10.3390/cells14070488 · Cited by 270
“Conversely, some chronic inflammatory diseases, such as rheumatoid arthritis, exhibit weaker or even protective effects against cancer development [7].”
Immunological Approaches Towards Cancer and Inflammation: A Cross Talk
Qu, X., Tang, Y., & Hua, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00563 · Cited by 301
“Similarly, TNF-α is considered as an anti-tumorigenic factor at high concentration (110); however, at moderate concentration, TNF-α can stimulate angiogenesis, metastasis, and cause damage to the DNA as shown in animal models (111).”
BackgroundMolecular mechanisms underlying chronic inflammation-associated cancers
Wu, Y., Antony, S., Meitzler, J. L., & Doroshow, J. H. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.08.014 · Cited by 308
“Inflammation also stimulates angiogenesis and tissue remodeling, both of which contribute to tumor cell invasion and metastasis [4–6].”
BackgroundBekes, E. M., Schweighofer, B., Kupriyanova, T. A., Zajac, E., Ardi, V. C., Quigley, J. P., & Deryugina, E. I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.031 · Cited by 298
Scheiner, B., Pomej, K., Kirstein, M. M., Hucke, F., Finkelmeier, F., Waidmann, O., Himmelsbach, V., Schulze, K., von Felden, J., Fründt, T. W., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.035 · Cited by 303
Metadata
- Authors
- Mantovani, A., Allavena, P., Sica, A., & Balkwill, F.
- Affiliations
- IRCCS Humanitas Research Hospital (IT)
- Fondazione Humanitas per la Ricerca (IT)
- Queen Mary University of London (GB)
- Venue
- Nature
- Published
- 2008-07-01
- Volume
- 454
- Issue
- 7203
- Pages
- 436-444
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2123105952
- Semantic Scholar
- b3a9e344a32ad6ca402d9149ac74b2b1df9e3076
- Cited by
- 11,399
- References
- 175
- Citations by year
- 2026: 419 · 2025: 554 · 2024: 655 · 2023: 761 · 2022: 848 · 2021: 878 · 2020: 864 · 2019: 759 · 2018: 752 · 2017: 732 · 2016: 692 · 2015: 683 · 2014: 643 · 2013: 574 · 2012: 510
- FWCI
- 26.32
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- tumor inflammation, tumor microenvironment, inflammatory mediators, angiogenesis, metastasis, immune evasion, chemoresistance, endocrine response, inflammatory signaling, therapeutic target
- MeSH terms
- Humans, Inflammation, Leukocytes, Neoplasm Invasiveness, Neoplasms, Oncogenes, Gonadal Steroid Hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.